| Literature DB >> 33006916 |
Wan-Chun Chang1,2, Reo Tanoshima1,2, Colin J D Ross2,3, Bruce C Carleton1,2,4.
Abstract
The clinical implementation of pharmacogenetic biomarkers continues to grow as new genetic variants associated with drug outcomes are discovered and validated. The number of drug labels that contain pharmacogenetic information also continues to expand. Published, peer-reviewed clinical practice guidelines have also been developed to support the implementation of pharmacogenetic tests. Incorporating pharmacogenetic information into health care benefits patients as well as clinicians by improving drug safety and reducing empiricism in drug selection. Barriers to the implementation of pharmacogenetic testing remain. This review explores current pharmacogenetic implementation initiatives with a focus on the challenges of pharmacogenetic implementation and potential opportunities to overcome these challenges.Entities:
Keywords: adverse drug reaction; clinical implementation; drug effectiveness; drug safety; pharmacogenetics; pharmacogenomics
Year: 2020 PMID: 33006916 DOI: 10.1146/annurev-pharmtox-030920-025745
Source DB: PubMed Journal: Annu Rev Pharmacol Toxicol ISSN: 0362-1642 Impact factor: 13.820